Surgery Partners AI Stock Analysis
Want to see SGRY full AI Analyst Report?
Surgery Partners (SGRY) AI Stock Analysis
Surgery Partners
(NASDAQ:SGRY)
Overall score is held back primarily by weak financial quality (sharp TTM revenue decline, ongoing net losses, and high leverage despite positive free cash flow). The latest earnings call is a support (reaffirmed guidance and leverage-reduction actions), while technicals show an uptrend but with overextended momentum. Valuation remains a headwind due to negative earnings and no dividend yield provided.
Surgery Partners (SGRY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.51B
- Dividend Yield
- ―
- Average Volume (3M)
- 3.94M
- Price to Earnings (P/E)
- -40.0
- Beta (1Y)
- 1.11
- Revenue Growth
- 2.19%
- EPS Growth
- 50.06%
- Country
- US
- Employees
- 16,000
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
Surgery Partners Business Overview & Revenue Model
Company Description
Surgery Partners, Inc. operates a nationwide network of surgical facilities and associated medical services across the United States. Its business is categorized into two segments: Surgical Facility Services and Ancillary Services. These surgical ven...
How the Company Makes Money
Surgery Partners primarily makes money by delivering surgical procedures and related services and collecting reimbursement from third-party payors and patients. Key revenue streams generally include: (1) Facility services revenue: fees earned by its...
Surgery Partners Earnings Call Summary
The call emphasized healthy organic performance (revenue growth, strong same-facility metrics, physician recruiting, case acuity expansion, sequential expense improvements) and a strategic portfolio optimization (Idaho Falls sale) expected to simplify the business, improve cash conversion and reduce leverage. Headwinds include a modest decline in adjusted EBITDA and margins year-to-date, higher interest expense, a ~350 bps decline in commercial mix, elevated leverage metrics, and muted M&A activity in 2026. On balance, the positives (organic growth, operational improvements, substantial deleveraging transaction and reaffirmed guidance) outweigh the negatives.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Surgery Partners reaffirmed full-year 2026 guidance of revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million (excluding any impact from the pending Idaho Falls transaction) and said it will update guidance promptly after that sale closes; the Idaho Falls transaction is expected to yield approximately $795 million of gross proceeds and reduce consolidated leverage by roughly 0.3 turns. For context, reported Q2 net revenue was about $849 million (up 2.7% YoY) with adjusted EBITDA of about $125 million and a 14.7% adjusted EBITDA margin, while year-to-date net revenue was about $1.66 billion (up 3.6%) with adjusted EBITDA of about $228 million; excluding Idaho Falls, Q2 revenue would have been roughly $660 million with adjusted EBITDA of roughly $98 million (H1 ex-Idaho Falls: ~$1.29 billion revenue and ~$173 million adjusted EBITDA). At quarter end liquidity and leverage metrics included cash of ~$217 million, revolver borrowings of ~$75 million with ~$618 million available capacity, credit-agreement net debt leverage of ~4.4x (balance-sheet net debt/EBITDA ~5.1x), Q2 operating cash flow of ~$59 million (YTD ~$71 million), and Q2 interest of ~ $90 million.
Surgery Partners Financial Statement Overview
Summary
Financial profile is mixed: operating profitability is solid (TTM EBIT margin ~12.0%, EBITDA margin ~14.6%) and free cash flow is positive (TTM FCF ~$202.8M), but TTM revenue declined sharply (-18.4%), the company is still net-loss making (TTM net margin ~-2.6%), and leverage remains elevated (debt ~$3.31B vs equity ~$1.66B; debt-to-equity ~2.0x), constraining flexibility.
Income Statement
46NeutralBalance Sheet
40NegativeCash Flow
62Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.36B | 3.31B | 3.11B | 2.74B | 2.54B | 2.23B |
| Gross Profit | 709.10M | 765.00M | 745.60M | 647.50M | 574.90M | 491.40M |
| EBITDA | 667.40M | 565.50M | 501.40M | 446.10M | 460.00M | 401.00M |
| Net Income | -87.00M | -77.90M | -168.10M | -11.90M | -54.60M | -70.90M |
Balance Sheet | ||||||
| Total Assets | 7.05B | 8.12B | 7.89B | 6.88B | 6.68B | 6.12B |
| Cash, Cash Equivalents and Short-Term Investments | 354.50M | 239.90M | 269.50M | 195.90M | 282.90M | 389.90M |
| Total Debt | 3.31B | 4.02B | 3.70B | 3.06B | 2.93B | 3.29B |
| Total Liabilities | 4.15B | 4.59B | 4.25B | 3.51B | 3.40B | 3.82B |
| Stockholders Equity | 1.66B | 1.71B | 1.79B | 1.99B | 2.00B | 1.09B |
Cash Flow | ||||||
| Free Cash Flow | 202.80M | 195.60M | 209.70M | 205.00M | 78.20M | 29.50M |
| Operating Cash Flow | 277.90M | 274.30M | 300.10M | 293.80M | 158.80M | 87.10M |
| Investing Cash Flow | 308.70M | -246.60M | -488.50M | -225.60M | -307.90M | -331.70M |
| Financing Cash Flow | -435.50M | -57.30M | 262.00M | -155.20M | 42.10M | 316.30M |
Surgery Partners Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGRY, the sentiment is Positive. The current price of 26.85 is above the 20-day moving average (MA) of 23.31, above the 50-day MA of 17.81, and above the 200-day MA of 15.21, indicating a bullish trend. The MACD of 2.82 indicates Negative momentum. The RSI at 87.84 is Negative, neither overbought nor oversold. The STOCH value of 91.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGRY.
Surgery Partners Risk Analysis
Surgery Partners disclosed 49 risk factors in its most recent earnings report. Surgery Partners reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksSurgery Partners Peers Comparison
Overall Rating
THC87Outperform
UHS76Outperform
ARDT68Neutral
HCA64Neutral
SGRY54Neutral
CYH44Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 87Outperform | $22.45B | 8.16 | 60.60% | ― | 6.23% | 136.09% | |
| 76Outperform | $11.07B | 8.01 | 19.54% | 0.42% | 8.00% | 13.14% | |
| 68Neutral | $2.50B | 17.08 | 9.48% | ― | 2.03% | -28.50% | |
| 64Neutral | $104.69B | 16.52 | -100.45% | 0.61% | 5.82% | 16.59% | |
| 54Neutral | $3.51B | -40.04 | -5.17% | ― | 2.19% | 50.06% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $284.87M | 7.57 | -2.51% | ― | -7.84% | -88.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SGRY | Surgery Partners Inc. | 26.85 | 11.14 | 70.91% | |
| CYH | Community Health Systems | 2.02 | -0.88 | -30.34% | |
| HCA | Hca Healthcare | 501.19 | 23.40 | 4.90% | |
| THC | Tenet Healthcare Corp. | 282.07 | 87.82 | 45.21% | |
| UHS | Universal Health Services | 191.98 | -34.97 | -15.41% | |
| ARDT | Ardent Health Partners, Inc. | 17.75 | 9.12 | 105.68% |
Surgery Partners Corporate Events
Surgery Partners Amends Merger Agreement, Reaffirms HealthSpan Transaction
PositiveOn November 8, 2026, Surgery Partners entered an amendment to its merger agreement with HealthSpan Partners after receiving an unsolicited third-party proposal on November 3, updated November 8. The amendment increased the cash consideration to $25 p...
Surgery Partners to be acquired by HealthSpan Partners
PositiveOn October 23, 2026, Surgery Partners agreed to be acquired by HealthSpan Partners, an affiliate of Bon Secours Mercy Health, through a merger that will take the surgical services company private. The all-cash transaction values Surgery Partners at a...
Surgery Partners Divests Hospital Assets to Cut Debt
PositiveOn September 14, 2026, Surgery Partners completed the sale of Mountain View Hospital, Idaho Falls Community Hospital, and associated subsidiaries to Intermountain Health for approximately $796.6 million in aggregate consideration, following physician...
Surgery Partners Reports Modest Q2 Revenue Growth, Net Loss
NeutralOn August 10, 2026, Surgery Partners reported that second-quarter 2026 revenue rose 2.7% year over year to $848.9 million, driven by a 5.0% increase in same-facility revenue and modest growth in case volumes, while adjusted EBITDA dipped to $125.2 mi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
